Cocrystal Pharma will present early results from its Phase 1b norovirus challenge study for CDI‑988 at the International Conference on Antiviral Research (ICAR) in Prague, scheduled for April 27–May 1 2026. The presentation, led by President and co‑CEO Dr. Sam Lee, will cover study design, enrollment progress, and early safety data.
CDI‑988 is an oral protease inhibitor that targets the 3CL protease of noroviruses and other coronaviruses. The Phase 1b study at Emory University School of Medicine is the first human challenge trial for the drug, and the presentation marks the first public disclosure of clinical data for CDI‑988, the company’s first pan‑viral oral antiviral candidate.
The presentation underscores the unmet medical need for norovirus treatment. With no approved antiviral therapies or vaccines, norovirus causes an estimated $60 billion in global economic impact each year. CDI‑988’s potential to treat both acute and chronic norovirus infection could fill a critical therapeutic gap.
Dr. Sam Lee said, “ICAR is widely regarded as the premier international conference for antiviral research, and it is a privilege to be selected to present our work to this antiviral research community.” He added, “We are excited to further advance CDI‑988 into a Phase 1b norovirus challenge study at Emory University School of Medicine. CDI‑988 is our first pan‑viral protease inhibitor developed for the treatment of acute norovirus gastroenteritis and also represents a significant step toward a potential treatment for patients suffering from chronic norovirus infection.”
The event signals progress toward a first‑in‑class oral antiviral for norovirus and highlights Cocrystal Pharma’s broader strategy to develop pan‑viral therapeutics. The presentation will provide the scientific community with early safety and efficacy signals that could shape the company’s development roadmap and potential regulatory strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.